Investigating a new antibody therapy for HIV-1 treatment

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy

['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-11058477

This study is testing a new type of treatment for HIV-1 that uses a special antibody designed to boost your immune system's ability to fight the virus, and it's for people living with HIV who want to see if this approach can help them better manage their condition.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorBRIGHAM AND WOMEN'S HOSPITAL (nih funded)
Locations1 site (BOSTON, UNITED STATES)
Trial IDNIH-11058477 on ClinicalTrials.gov

What this research studies

This research focuses on a novel treatment approach for HIV-1 using a trispecific broadly neutralizing antibody (bnAb) therapy. The therapy aims to enhance the immune response against HIV by combining three different antibody binding sites into one molecule, potentially improving the effectiveness of treatment. Patients will be monitored for safety and how well the therapy works in reducing the virus in their bodies. This approach could lead to longer-lasting effects compared to traditional treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals living with HIV-1 who have not responded adequately to existing treatments.

Not a fit: Patients who are not infected with HIV-1 or those who have advanced AIDS may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could provide a more effective and long-lasting treatment option for individuals living with HIV-1.

How similar studies have performed: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, but this specific trispecific approach is novel.

Where this research is happening

BOSTON, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, acquired immunodeficiency syndrome clinical trial group, Acquired Immunodeficiency Syndrome Virus

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.